Dementia Therapeutics Market is Forecast to Show Significant Growth until 2017. The report is an essential source of information and analysis on the global dementia market.
Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.
Dementia Therapeutics Market is Forecast to Show Significant Growth until 2017
GlobalData estimated the dementia therapeutics market in 2010 to be worth $6.6 billion and forecasts it to grow at 10.5% annually for the next seven years to reach $13.4 billion by 2017. This significant growth is primarily attributed to increasing therapeutic options for the treatment of dementia. In addition, the successful launch of some of the molecular targeted therapies, such as bapineuzumab and GAMMAGARD LIQUID, currently in Phase III, may significantly stimulate market growth in the near future. However, delayed diagnosis and the patent expiry of some approved products in the current year and the coming years will continue to be a barrier for market growth.
Current Treatment Options are Moderately Successful in Meeting Market Demand
GlobalData analysis points out that the current competition in the dementia therapeutics market is weak and available treatment options have been moderately successful in meeting market demand.
The products currently available in the market provide only symptomatic relief. Pfizer’s Aricept (donepezil) continues to lead the market, followed by Novartis’ Exelon (rivastigimine). The other drug classes are comprised of Forest
Laboratories’ Namenda (memantine), Johnson and Johnson’s Razadyne (galantamine hydrobromide) and Eisai’s Cognex (tacrine). As the products currently available do not serve the market’s unmet needs, the market continues to present opportunities for stronger pipeline candidates. The extent of unmet needs in the market is considered to be at a high level and can be fulfilled by technologically advanced products possessing improved safety and efficacy profiles.
Strong Pipeline Candidates are Expected to Intensify Future Competition
GlobalData found that there are 38 products in different stages of development. Bapineuzumab and GAMMAGARD LIQUID, currently in Phase III are the most promising products in the pipeline. These molecules have shown encouraging response rates in pretreated patients and have disease modifying abilities in the dementia therapeutics market. If approved, other pipeline candidates such as solanezumab and abilify which are currently in Phase III will provide alternative treatment options to the current therapies. These products are expected to meet some of the unmet needs and will provide physicians with a better choice in treating dementia. It may also lead to an intensely competitive market. In summary, the dementia therapeutics market is heading towards a highly competitive landscape.
High Unmet Need in the Dementia Therapeutics Market Razadyne (galantamine hydrobromide) and Eisai’s Cognex (tacrine). As the products currently available do not serve the market’s unmet needs, the market continues to present opportunities for stronger pipeline candidates. The extent of unmet needs in the market is considered to be at a high level and can be fulfilled by technologically advanced products possessing improved safety and efficacy profiles.
The dementia therapeutics market has significant unmet needs. This implies that the market is moderately served by the current products with much scope available for the launch of improved products that can capture the dementia therapeutics market. The approved drugs for dementia therapeutics have low efficacy and safety profiles and provide only symptomatic treatment for the disease. The fact that current therapeutic landscape for dementia has products providing relief for the symptoms of the disease means that a product that can alter the progression of the disease is likely to achieve blockbuster status and will have the potential to capture a significant share of the market.
GlobalData, the industry analysis specialist, has released its new report, “Dementia Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global dementia market. The report identifies the key trends shaping and driving the global dementia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global dementia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Visit our report store: http://www.globaldata.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782